{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:22:34Z","timestamp":1761218554328,"version":"3.37.3"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","award":["P50-CA136393"],"award-info":[{"award-number":["P50-CA136393"]}],"id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ygyno.2023.01.021","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T23:32:12Z","timestamp":1674862332000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer"],"prefix":"10.1016","volume":"170","author":[{"given":"T.M.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.L.","family":"Lebreton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.E. Wahner","family":"Hendricksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Oberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Glaspy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.E.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.L.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.01.021_bb0005","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0010","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie ovarian Cancer study group, a randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0015","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian Cancer","volume":"11","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0020","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 trial of bevacizumab in ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0025","first-page":"null","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer","volume":"0","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0030","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0035","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0040","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ctrv.2017.08.012","article-title":"IGF system targeted therapy: therapeutic opportunities for ovarian cancer","volume":"60","author":"Liefers-Visser","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ghir.2014.10.002","article-title":"The dichotomy of the insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?","volume":"25","author":"Crudden","year":"2015","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0055","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/1535-7163.MCT-05-0048","article-title":"Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody","volume":"4","author":"Wang","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.bjc.6602963","article-title":"Targeting insulin-like growth factor pathways","volume":"94","author":"Yee","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.01.021_bb0065","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1006\/excr.1997.3861","article-title":"Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system","volume":"238","author":"Conover","year":"1998","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0070","first-page":"2947","article-title":"Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy, Clin. Cancer res. Off. J. Am. Assoc","volume":"20","author":"Beltran","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0075","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0080","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"MRC OV05, EORTC 55955 investigators, early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0085","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","article-title":"Phase I, pharmacokinetic, and Pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1","volume":"27","author":"Tolcher","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2023.01.021_bb0090","first-page":"32","article-title":"Effects of growth hormone on glucose metabolism","volume":"36","author":"M\u00f8ller","year":"1991","journal-title":"Horm. Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0095","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/0008-5472.CAN-08-3153","article-title":"Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian Cancer cells","volume":"69","author":"Eckstein","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2021.09.025","article-title":"Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer","volume":"163","author":"Konecny","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.onc.1204050","article-title":"Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells","volume":"20","author":"Bala\u00f1\u00e1","year":"2001","journal-title":"Oncogene."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0110","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.2011.37.2359","article-title":"Phase II study of Ganitumab, a fully human anti\u2013Type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors","volume":"30","author":"Tap","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0115","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdt057","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer\u2020","volume":"24","author":"Cohn","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0120","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdv027","article-title":"A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial\u2020","volume":"26","author":"Fuchs","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0125","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1158\/1078-0432.CCR-13-2752","article-title":"Randomized Phase Ib\/II trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab alone in patients with wild-type KRAS metastatic colorectal Cancer","volume":"20","author":"Van Cutsem","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0130","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-13-1869","article-title":"Phase II Randomized study of Figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate Cancer","volume":"20","author":"de Bono","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0135","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdu517","article-title":"Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer","volume":"26","author":"Scagliotti","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-3-26","article-title":"Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with non-small-cell lung cancer: a phase I\/II randomized trial","volume":"3","author":"Moran","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0145","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/cncr.29308","volume":"121","author":"Hanna","year":"2015","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(13)70026-3","article-title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","volume":"14","author":"Robertson","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.54.4932","article-title":"Randomized, Phase III trial of first-line Figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non\u2013small-cell lung Cancer","author":"Langer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0160","doi-asserted-by":"crossref","first-page":"djv258","DOI":"10.1093\/jnci\/djv258","article-title":"II\/III study of Dalotuzumab in combination with Cetuximab and irinotecan in Chemorefractory, KRAS wild-type, metastatic colorectal Cancer, JNCI","volume":"107","author":"Sclafani","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0165","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mds142","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer","volume":"23","author":"Kindler","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0170","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.bcp.2008.07.027","article-title":"Characterization of IRA\/IRB hybrid insulin receptors using bioluminescence resonance energy transfer","volume":"76","author":"Blanquart","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0175","doi-asserted-by":"crossref","first-page":"14326","DOI":"10.1021\/bi9613032","article-title":"Characterization of a hybrid receptor formed by dimerization of the insulin receptor-related receptor (IRR) with the insulin receptor (IR): coexpression of cDNAs encoding human IRR and human IR in NIH-3T3 cells","volume":"35","author":"Jui","year":"1996","journal-title":"Biochemistry."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20061709","article-title":"Characterization of insulin\/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation","volume":"403","author":"Benyoucef","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0185","doi-asserted-by":"crossref","first-page":"39684","DOI":"10.1074\/jbc.M202766200","article-title":"Insulin\/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved*","volume":"277","author":"Pandini","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0190","doi-asserted-by":"crossref","first-page":"27643","DOI":"10.1074\/jbc.M108863200","article-title":"Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor*","volume":"277","author":"Gilmore","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0195","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1158\/0008-5472.CAN-06-1684","article-title":"Heterodimerization of insulin-like growth factor receptor\/epidermal growth factor receptor and induction of Survivin expression counteract the antitumor action of Erlotinib","volume":"66","author":"Morgillo","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0200","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2007.02.012","article-title":"The EGF receptor interacts with the type 1 IGF receptor and regulates its stability","volume":"355","author":"Riedemann","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0205","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1158\/1535-7163.MCT-08-0493","article-title":"HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924","volume":"7","author":"Haluska","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1530\/JOE-13-0306","article-title":"IGF1R blockade with ganitumab results in systemic effects on the GH\u2013IGF axis in mice","volume":"221","author":"Moody","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0215","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti\u2013insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.01.021_bb0220","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.23.6745","article-title":"Phase I, pharmacokinetic, and Pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1","author":"Tolcher","year":"2009","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:50:52Z","timestamp":1715820652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"alternative-id":["S0090825823000215"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}